Attributes and Health Care Resource Utilization of Patients on Enzalutamide or Abiraterone for Metastatic Castration-Resistant Cancer in England
Patients with mCRPC on ENZA or AA had generally similar baseline characteristics apart from diabetes prevalence. ENZA was associated with longer OS and treatment duration, and lower HCRU after treatment initiation than AA.
Authors
- Gerhardt Attard (ORCID: https://orcid.org/0000-0002-4811-7983)
- Robert Snijder (ORCID: https://orcid.org/0000-0002-5495-8287)
- Axel S. Merseburger (ORCID: https://orcid.org/0000-0001-6467-3931)
- Rita Faria (ORCID: https://orcid.org/0000-0003-3410-1435)
- Andrew Chilelli (ORCID: https://orcid.org/0009-0006-7086-4703)
- Nigel Rozario (ORCID: https://orcid.org/0000-0003-1510-1675)
- Amit K. Bahl (ORCID: https://orcid.org/0000-0002-8525-0310)
- A. Pranzo
- Karla Martins (ORCID: https://orcid.org/0000-0002-5306-7124)
- H. Sodatonou
- Sari Stark
- Jess Ridsdale‐Smith (ORCID: https://orcid.org/0009-0006-8770-7982)
Institutions
- University Hospitals Bristol NHS Foundation Trust (GB)
- IQVIA (United Kingdom) (GB)
- Astellas Pharma (United Kingdom) (GB)
- University Hospital Schleswig-Holstein (DE)
- University College London (GB)
- University of Lübeck (DE)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1200/op-24-01045
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52